WHAT IS CLAIMED IS:

1. Use of epacadostat, or a pharmaceutically acceptable salt thereof and an antibody, or an antigen-binding fragment thereof, that binds to human PD-1, in the manufacture of a medicament for treatment of cancer in a patient, wherein the medicament is to be administered to said patient and comprises:

(i) epacadostat, or a pharmaceutically acceptable salt thereof, at a dose from 400 mg to 700 mg on a free base basis BID; and

(ii) an antibody, or an antigen-binding fragment thereof, that binds to human PD-1, wherein the antibody comprises (ii-1) a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3; and (ii-2) a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3; wherein:

(a) the VH CDR1 comprises the amino acid sequence SYWMN (**SEQ ID NO:6**);

(b) the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (**SEQ ID NO:7**);

(c) the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (**SEQ ID NO:8**);

(d) the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (**SEQ ID NO:9**);

(e) the VL CDR2 comprises the amino acid sequence AASNQGS (**SEQ ID NO:10**); and

(f) the VL CDR3 comprises the amino acid sequence QQSKEVPYT (**SEQ ID NO:11**).

2. The use of claim 1, wherein the epacadostat is the free base.

3. The use of claim 2, wherein the epacadostat is at a dose of 400 mg BID.

4. The use of claim 2, wherein the epacadostat is at a dose of 425 mg BID.

5. The use of claim 2, wherein the epacadostat is at a dose of 450 mg BID.

6. The use of claim 2, wherein the epacadostat is at a dose of 475 mg BID.

7. The use of claim 2, wherein the epacadostat is at a dose of 500 mg BID.

8. The use of claim 2, wherein the epacadostat is at a dose of 525 mg BID.

9. The use of claim 2, wherein the epacadostat is at a dose of 550 mg BID.

10. The use of claim 2, wherein the epacadostat is at a dose of 575 mg BID.

11. The use of claim 2, wherein the epacadostat is at a dose of 600 mg BID.

12. The use of any one of claims 1-11, wherein the antibody is at a dose of 500 mg.

13. The use of any one of claims 1-11, wherein the antibody is at a fixed dose of 500 mg and the medicament is to be administered once every four weeks.

14. The use of any one of claims 1-11, wherein the antibody is at a fixed dose of 375 mg and the medicament is to be administered once every 3 weeks.

15. The use of any one of claims 1-14, wherein the medicament comprising the antibody is to be administered *via* intravenous administration.

16. The use of any one of claims 1-15, wherein the VH domain comprises the amino acid sequence set forth in **SEQ ID NO:4**.

17. The use of any one of claims 1-16, wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in **SEQ ID NO:2**.

18. The use of any one of claims 1-17, wherein the VL domain comprises the amino acid sequence set forth in **SEQ ID NO:5**.

19. The use of any one of claims 1-18, wherein the antibody comprises a light chain and wherein the light chain comprises the amino acid sequence set forth in **SEQ ID NO:3**.

20. The use of any one of claims 1-19, wherein the VH domain comprises the amino acid sequence set forth in **SEQ ID NO:4** and the VL domain comprises the amino acid sequence set forth in **SEQ ID NO:5**.

21. The use of any one of claims 1-20, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in **SEQ ID NO:2** and the light chain comprises the amino acid sequence set forth in **SEQ ID NO:3**.

22. The use of any one of claims 1-21, wherein the antibody comprises an Fc Region of the IgG4 isotype and an IgG4 Hinge Domain that comprises a stabilizing mutation.

23. The use of any one of claims 1-22, wherein the antibody is a humanized antibody.

24. The use of any one of claims 1-23, wherein the cancer is a solid tumor.

25. The use of any one of claims 1-24, wherein the cancer is skin cancer, lung cancer, lymphoma, sarcoma, bladder cancer, cancer of the ureter, urethra, and urachus, gastric cancer, cervical cancer, liver cancer, breast cancer, renal cancer, head and neck cancer, squamous cell carcinoma, colorectal cancer, endometrial cancer, anal cancer, and a tumor with microsatellite instability-high (MSI-H), mismatch repair deficient (dMMR) or DNA polymerase ε exonuclease domain mutation positive disease.

26. The use of any one of claims 1-24, wherein the cancer is cholangiocarcinoma, melanoma, non-small cell lung cancer, small cell lung cancer, Hodgkin's lymphoma, urothelial carcinomagastric cancer, hepatocellular carcinoma, Merkel cell carcinoma, triple-negative breast cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, and colorectal cancer.

27. The use of any one of claims 1-24, wherein the cancer is squamous cell carcinoma of the anal canal.

28. The use of any one of claims 1-24, wherein the cancer is Merkel cell carcinoma.

29. The use of any one of claims 1-24, wherein the cancer is endometrial cancer.

30. The use of any one of claims 1-24, wherein the cancer is cervical cancer.

31. The use of any one of claims 1-24, wherein the cancer is renal cancer.

32. The use of claim 31, wherein the cancer is kidney renal clear cell carcinoma.

33. The use of any one of claims 1-24, wherein the cancer is lung cancer.

34. The use of claim 33, wherein the cancer is adenocarcinoma of the lung.

35. The use of claim 33, wherein the cancer is squamous cell carcinoma of the lung.

36. The use of claim 33, wherein the cancer is non-small cell lung cancer.

37. The use of any one of claims 1-24, wherein the cancer is head and neck cancer.

38. The use of claim 37, wherein the cancer is head and neck squamous cell carcinoma.

39. The use of any one of claims 1-24, wherein the cancer is bladder cancer.

40. The use of claim 39, wherein the bladder cancer is high risk BCG-unresponsive non-muscle invasive bladder cancer.

41. The use of any one of claims 1-40, wherein the cancer is microsatellite-stable (MSS).

42. The use of any one of claims 1-40, wherein the cancer is PD-L1 positive.

43. The use of any one of claims 1-41, wherein the cancer is microsatellite-stable (MSS) and PD-L1 positive.